Stem Cell Therapy Regulation in Canada: Implications of the Prochymal Approval

On May 17, 2012, Health Canada issued marketing approval for Prochymal, a stem cell therapy used to treat children with acute Graft versus Host Disease (aGvHD). The development was heralded as the first stem cell product approved by regulatory authorities in the world.

In this case, Health Canada outpaced the USFDA, which is still requesting further clinical data from the manufacturer, Osiris Therapeutics Inc.


To read the full article, download the PDF here.

To discuss these issues, please contact the author(s).

This publication is a general discussion of certain legal and related developments and should not be relied upon as legal advice. If you require legal advice, we would be pleased to discuss the issues in this publication with you, in the context of your particular circumstances.

For permission to republish this or any other publication, contact Janelle Weed.

© 2017 by Torys LLP.
All rights reserved.

Tags: